Dr. Vogelzang on Cabozantinib Clinical Trial Results

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada discusses the cabozantinib clinical trial results.

Dr. Vogelzang says hepatocellular, melanoma, lung and breast cancer patients had minorities of patients, somewhere between 20% and 40% of patients in the trial. In the subset of hepatocellular, over 50% of patients had clinical benefit, namely either tumor shrinkage, dropping of blood tests, reduced pain, etc. The groups that didn't seem to benefit were the gastrointestinal tumor population and the small cell lung cancer population. The ovarian cancer and prostate cancer groups were so obviously benefitting that they were reported as individual reports.